CLSD (CLSD)
Clearside Biomedical, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
USClearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space.
Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema.
The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials.
Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Leadership
Dr. Ciulla
Chief Medical Officer and Chief Development Officer
Employees
32
Country
US
Sector
Healthcare
Website
clearsidebio.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Thorp Clay | Director | Purchase | 15.0K | $13.8K | Feb 24, 2025 |
 Deignan Charles A. | Chief Financial Officer | Grant/Award | 200.0K | -- | Jan 8, 2025 |
 Chong Ngai Hang Victor | Chief Medical Officer | Grant/Award | 250.0K | -- | Jan 8, 2025 |
 LASEZKAY GEORGE M | CEO | Grant/Award | 500.0K | -- | Jan 8, 2025 |
| Chong Ngai Hang Victor | Chief Medical Officer | Purchase | 36.5K | $36.5K | Nov 1, 2024 |
| Name | Shares | % | Source |
|---|---|---|---|
DRW Securities, LLC | 27.1K | -- | 13F |
 Thorp Clay Director | 11.7K | -- | FORM 4 |
 Chong Ngai Hang Victor Chief Medical Officer | 6.7K | -- | FORM 4 |
Insiders
- Thorp ClayDirector
- Deignan Charles A.Chief Financial Officer
- Chong Ngai Hang VictorChief Medical Officer
- LASEZKAY GEORGE MCEO
Top institutional holders
US30d Avg
--
60d Avg
--
90d Avg
--